Novartis (NVS) (OTCPK:NVSEF) has announced that its next-generation malaria treatment, KLU156 (GanLum), developed with Swiss ...

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction ...

Trodelvy did not meet the primary endpoint of progression-free survival in the ASCENT-07 trial for HR-positive, HER2-negative ...

SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor ...

Despite the trial failure, Sarepta will still seek full approval of AMONDYS 45 and VYONDYS 53 in DMD from the FDA.

Trodelvy didn't improve progression-free survival versus chemo in the post-endocrine therapy first-line HR-positive, HER2-negative advanced breast cancer setting.

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

The aftermath of the Michelin Guide ceremony has stoked various reactions of but everyone should not miss the forest for the trees ...

The drug finerenone has a positive effect on patients with type 1 diabetes and chronic kidney disease. The drug reduces the ...

WASHINGTON -- An investigational dual therapy appeared to show antiviral activity in patients with chronic hepatitis D virus (HDV) infection, according to the phase II SOLSTICE trial.

The Russian hacker group Curly COMrades is abusing Microsoft Hyper-V in Windows to bypass endpoint detection and response ...